ICD-10 and Oncology – How ICD-10 CM Impacts Cancer Registries – Commission on Cancer Participants

ICD-10 will impact Cancer registries, sometimes called “tumor registries.”

Today these registries rely on ICD-9-CM codes for diagnoses and procedures that are subsequently stored in electronic medical records. Cancer registrars use the ICD-9-CM codes for case finding.   In some states,  disease indices for case finding are dependent on these codes. Medical coding is one of the casef inding primary resources for cancer registrars.

The American College of Surgeons (ACoS) established the Commission on Cancer (CoC) in 1922.  The CoC are designed to ensure quality, multi- disciplinary, comprehensive cancer care delivery.  The CoC conducts health care surveys to assess compliance with standards, and it collects data from accredited providers to measure cancer care quality.

If you are in a CoC hospital registry, you are also collecting complications and co morbidities, which are ICD-9-CM codes.  These codes will be replaced by  ICD-10-CM.

Member organizations in the CoC include:

American Academy of Hospice and Palliative Medicine (AAHPM)

American Academy of Pediatrics (AAP)

American Association for Cancer Education (AACE)

American Cancer Society (ACS)

American College of Obstetricians and Gynecologists (ACOG)

American College of Oncology Administrators (ACOA)

American College of Physicians (ACP)

American College of Radiology (ACR)

American College of Surgeons (ACoS)

American College of Surgeons Committee on Young Surgeons (ACOSCYS)

American College of Surgeons Oncology Group (ACOSOG)

American College of Surgeons Resident and Associate Society (ACOSRAS)

American Dietetic Association (ADA)

American Head and Neck Society (AHNS)

American Hospital Association (AHA)

American Joint Committee on Cancer (AJCC)

American Medical Association (AMA)

American Pediatric Surgical Association (APSA)

American Psychosocial Oncology Society (APOS)

American Radium Society (ARS)

American Society of Breast Surgeons (ASBS)

American Society of Clinical Oncology (ASCO)

American Society of Colon and Rectal Surgeons (ASCRS)

American Society for Radiation Oncology (ASRO)

American Urological Association (AUA)

Association of American Cancer Institutes (AACI)

Association of Cancer Executives (ACE)

Association of Community Cancer Centers (ACCC)

Association of Oncology Social Work (AOSW)

Canadian Society of Surgical Oncology (CSSO)

Centers for Disease Control and Prevention (CDC)

College of American Pathologists (CAP)

Department of Defense (DoD)

Department of Veterans Affairs (VA)

International Union Against Cancer—UICC (IUAC/UICC)

National Cancer Institute: Surveillance, Epidemiology, and End Results (SEER) Program (NCI/SEER)

National Cancer Institute: Outcomes Research

National Cancer Registrars Association (NCRA)

National Comprehensive Cancer Network (NCCN)

National Consortium of Breast Cancer, Inc. (NCBC)

National Society of Genetic Counselors (NSGC)

National Surgical Adjuvant Breast and Bowel Project (NSABP)

North American Association of Central Cancer Registries (NAACCR)

Oncology Nursing Society (ONS)

Society of Gynecologic Oncologists (SGO)

Society of Nuclear Medicine (SNM)

Society of Surgical Oncology (SSO)

Society of Thoracic Surgeons (STS)

Michael F. Arrigo

Michael is Managing Partner & CEO of No World Borders, a leading healthcare management and IT consulting firm. He serves as an expert witness in Federal and State Court and was recently ruled as an expert by a 9th Circuit Federal Judge. He serves as a patent expert witness on intellectual property disputes, both as a Technical Expert and a Damages expert. His vision for the firm is to continue acquisition of skills and technology that support the intersection of clinical data and administrative health data where the eligibility for medically necessary care is determined. He leads a team that provides litigation consulting as well as advisory regarding medical coding, medical billing, medical bill review and HIPAA Privacy and Security best practices for healthcare clients, Meaningful Use of Electronic Health Records. He advises legal teams as an expert witness in HIPAA Privacy and Security, medical coding and billing and usual and customary cost of care, the Affordable Care Act and benefits enrollment, white collar crime, False Claims Act, Anti-Kickback, Stark Law, physician compensation, Insurance bad faith, payor-provider disputes, ERISA plan-third-party administrator disputes, third-party liability, and the Medicare Secondary Payer Act (MSPA) MMSEA Section 111 reporting. He uses these skills in disputes regarding the valuation of pharmaceuticals and drug costs and in the review and audit of pain management and opioid prescribers under state Standards and the Controlled Substances Act. He consults to venture capital and private equity firms on mHealth, Cloud Computing in Healthcare, and Software as a Service. He advises ERISA self-insured employers on cost of care and regulations. Arrigo was recently retained by the U.S. Department of Justice (DOJ) regarding a significant false claims act investigation. He has provided opinions on over $1 billion in health care claims and due diligence on over $8 billion in healthcare mergers and acquisitions. Education: UC Irvine - Economics and Computer Science, University of Southern California - Business, studies at Stanford Medical School - Biomedical Informatics, studies at Harvard Medical School - Bioethics. Trained in over 10 medical specialties in medical billing and coding. Trained by U.S. Patent and Trademark Office (USPTO) and PTAB Judges on patent statutes, rules and case law (as a non-attorney to better advise clients on Technical and Damages aspects of patent construction and claims). Mr. Arrigo has been interviewed quoted in the Wall Street Journal, New York Times, and National Public Radio, Fortune, KNX 1070 Radio, Kaiser Health News, NBC Television News, The Capitol Forum and other media outlets. See https://www.noworldborders.com/news/ and https://www.noworldborders.com/clients/ for more about the company.

Leave a Reply